DUBLIN, Aug. 17, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/ljlbvg/investigation) has announced the addition of the "Investigation Report on China's Follicle-Stimulating Hormone (FSH) Market, 2010-2019" report to their offering.
According to the WHO's evaluation, one in seven couples suffer from infertility which influences about 10%-15% of the world population. According to a survey, the number of patients with infertility accounts for 10% of married people, doubling at 4.8% in 1984. The incidence of infertility in young people has increased and it is 15%-20% among women of childbearing age. For patients with hypothalamic-pituitary dysfunction including polycystic ovary syndrome, FSH can promote follicular development while in the case of blocked fallopian tube, unexplained infertility and infertility caused by male factor, FSH can do so in the assistive technology used to conceive the child.
FSH brought in a global sales value of over USD 1.2 billion in 2013 to which Gonal-f (FSHa) made by Merck Serono contributed USD 813 million with a market share of 63% while Puregon (FSHß) of Merck contributed USD 481 million with a market share of 37%. FSH developed fast after entering China, with annual sales value rising from less than CNY 2 million in 2006 to CNY 215 million in 2014 and the CAGR during this period reached 84.2%. Merck Serono (rhFSHa), Livzon Pharmaceutical Group Co., Ltd (UFSH), IBSA (UFSH) and Organon (rhFSHß) dominate the Chinese market, among of which Livzon Pharmaceutical Group Co., Ltd has the largest market share of about 59% for sales value in 2014.
Key Topics Covered:
1 Related Concepts of FSH
2 Market Profile of FSH in China
3 Survey on Sales Status of FSH in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of FSH in China, 2010-2014
5 Survey on Dosage Forms of FSH in China, 2010-2014
6 Reference Price of FSH in Chinese Hospitals in 2014
7 Major Manufacturers of FSH in Chinese Market, 2010-2014
8 Market Outlook of FSH in China, 2015-2019
- Livzon Pharmaceutical Group Co., Ltd
- Merck Serono
- IBSA Institut Biochimique SA
For more information visit http://www.researchandmarkets.com/research/ljlbvg/investigation
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets